A Histology-Independent Study of the Cyclin Inhibitor Palbociclib in Patients With Advanced Cancer Harboring Aberrations in the Cyclin Pathway

Trial Profile

A Histology-Independent Study of the Cyclin Inhibitor Palbociclib in Patients With Advanced Cancer Harboring Aberrations in the Cyclin Pathway

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2017 Planned End Date changed from 1 Apr 2024 to 1 Feb 2024.
    • 20 Oct 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Feb 2020.
    • 20 Oct 2017 Planned initiation date changed from 1 May 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top